0.30Open0.30Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover69.12%IV10.13%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type-0.3549Delta0.4367Gamma23.24Leverage Ratio-0.0076Theta-0.0011Rho-8.25Eff Leverage0.0046Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet